Gland Pharma to announce four complex injectables during FY22; Q2 profit rises 38%

Senores Pharmaceuticals IPO: Should you subscribe? Check GMP, subscription

The Rs 582.11 crore initial public offering of Senores Pharmaceuticals is set to close for bidding on Tuesday, December 24, 2024, after opening for subscription on Friday. Before the public offering, Senores Pharmaceuticals raised Rs 260.6 crore from anchor investors by allocating 66.65 lakh shares at Rs 391 per share. Notable investors in the anchor book include Goldman Sachs, Societe …

Pharmaceuticals Company Bsc Shares Ipo Gmp Senores Pharmaceuticals

4 days, 19 hours ago

Senores Pharmaceuticals IPO: Check latest GMP, price band and should you apply?

India Today

Senores Pharmaceuticals' initial public offering, valued at Rs 582.11 crore, opened for bidding on December 20, 2024, and will close on December 24. The IPO consists of a fresh issue of Rs 500 crore and an offer-for-sale of up to 21 lakh shares by promoters and existing shareholders. According to market watchers, the latest grey market premium for the IPO …

Pharmaceutical Shares Ipo Senores Pharmaceuticals Senores

5 days, 3 hours ago

Senores Pharmaceuticals IPO raises ₹261 crore from anchor investors ahead of public issue

Live Mint

New Delhi, Dec 19 Senores Pharmaceuticals Ltd on Thursday said it has secured nearly ₹261 crore from anchor investors, ahead of its initial share-sale opening for public subscription. ICICI Prudential Mutual Fund, Mahindra Manulife Mutual Fund, Aditya Birla Sun Life Insurance Company, SBI General Insurance Company, and Troo Capital are among the anchor investors, according to a circular uploaded on …

Company Crore Pti Shares Ipo Senores Pharmaceuticals Senores

3 weeks ago

Sanofi to invest 1b euros in insulin production base in Beijing

China Daily

Sanofi to invest 1b euros in insulin production base in Beijing Xinhua Updated: Dec 03, 2024 The Sanofi booth at the 7th CIIE in Shanghai, on Nov 7, 2024. BEIJING -- French pharma giant Sanofi will invest some 1 billion euros to establish a new insulin production base in Beijing, according to the Beijing Economic-Technological Development Area. Sanofi Chief Executive …

China Production Beijing Base Bda Sanofi Insulin Production Base

3 weeks, 6 days ago

Healthcare Sector Could Touch $638 Billion in 2025

Deccan Chronicle

Chennai: The Indian healthcare sector is projected to reach $638 billion by 2025 with hospitals, pharmaceuticals and diagnostics seeing faster growth post the pandemic. Valued at $110 billion in 2016, the Indian healthcare market reached $372 billion in 2023, marking a 22.5 per cent CAGR growth and is expected to touch $638 billion in 2025. The sector has seen a …

Healthcare Billion Cent

1 month ago

Bulk drug makers to benefit from price stability but need to improve efficiency to compete with Chinese rivals: Experts

Live Mint

Mumbai: Softening prices of active pharmaceutical ingredients are likely to stabilise in the months ahead and bring relief to Indian manufacturers, but they will still have to improve their operational efficiency to compete against Chinese rivals, industry executives and analysts said. API prices have been falling for the past 12-15 months, driven mainly by sharp price cuts by Chinese companies, …

India China Drugs Indian Prices Price Pharma

1 month ago

Onyx Biotec Listing: Stock makes weak market debut, lists 11.5% below issue price

Live Mint

Onyx Biotec Listing: Onyx Biotec made a weak market debut on Friday, November 22 as its shares were listed at ₹54 each on NSE SME, an 11.50% discount to the issue price of ₹61. The company intends to use the net proceeds from the IPO for several purposes, such as upgrading its existing Manufacturing Unit I to produce large-volume parenteral …

Company Limited Unit Onyx Biotec Sterile Water Market Debut

1 month, 1 week ago

Glenmark Pharmaceuticals Q2 results 2024 on 16 Nov, 2024: profit at ₹354.21Cr, Revenue increased by 7.06% YoY

Live Mint

Glenmark Pharmaceuticals Q2 Results 2024:Glenmark Pharmaceuticals declared its Q2 results on 14 Nov, 2024, reporting a significant turnaround with a profit of ₹354.21 crore. As of 16 Nov, 2024, Glenmark Pharmaceuticals has a market cap of ₹43,279.2 crore, with a 52-week high of ₹1,830.95 and a low of ₹746.55. The consensus recommendation among analysts as of 16 Nov, 2024, is …

Pharmaceuticals Rating Results 2024 Glenmark Pharmaceuticals Glenmark 16 Nov

1 month, 1 week ago

JB Pharma, Sun, Torrent ,Lupin, Abbott lead pharma market growth in October

Live Mint

India Pharma Market: Nifty Pharma index has seen a decline of 4% in November. While the selling pressure in the domestic markets has led to the this decline, the Indian Pharma Market growth also was not very encouraging in October albeit on a high base. In October’24, Indian Pharma Market continued to exhibit moderate growth of sub 5% Year on …

Indian New Launches Ipm Yoy Growth Centrum Growth Lupin Pharmaceuticals Market

1 month, 1 week ago

Top News on Nov 14: Market slides for 6th day, Reliance, Disney complete transaction, Q2 results, GRAP 3 In Delhi, more

Live Mint

From Sensex, Nifty 50 sliding for 6th day to Reliance-Disney completing transaction to imposition of GRAP 3 In Delhi, here are today's top stories. Reliance, Disney complete transaction for $8.5-billion merger deal to create India’s largest media powerhouse Reliance-Disney merger: Mukesh Ambani-led Reliance Industries has completed the merger of its media assets with the India business of global media house …

India Delhi Disney Reliance Industries Quarter Net Read

1 month, 1 week ago

Glenmark Pharma Q2 Results: Pharma major posts net profit of ₹354.48 crore, revenue up 7.5% YoY

Live Mint

Glenmark Pharma Q2 Results: Glenmark Pharmaceuticals Limited announced its July to September quarter results on Thursday, November 14. The company posted a ₹354.48 crore net profit in the second quarter of the financial year 2024-25. Glenmark Pharma posted a net loss of ₹180.29 crore in the same quarter the previous year, according to the company's BSE filing on Thursday. Glenmark …

Crore Quarter Glenmark Pharma Results Pharma Glenmark Posts Net

1 month, 1 week ago

AstraZeneca Q2 net profit declines 27%, revenue up 31%

Live Mint

Mumbai: AstraZeneca Pharma India Ltd posted a profit after tax of ₹38 crore, down 27% year-on-year, in the September quarter of FY25. The company’s revenue growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments, Bhavana Agrawal, chief financial officer of the company, said in a release on Wednesday. Palivizumab, also known by the …

India

1 month, 1 week ago

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY

Live Mint

Suven Pharmaceuticals Q2 Results Live : Suven Pharmaceuticals declared their Q2 results on 12 Nov, 2024, showcasing a robust performance with a topline increase of 11.54% year-over-year. In comparison to the previous quarter, Suven Pharmaceuticals reported an impressive revenue growth of 11.72% along with a significant profit increase of 35.28%. As of 13 Nov, 2024, all analysts covering the company …

Pharmaceuticals Suven Pharmaceuticals Suven Growth Q2

1 month, 1 week ago

Natco Pharma Q2 Results Live: Profit Rises by 83.55% YoY

Live Mint

Natco Pharma Q2 Results Live : Natco Pharma announced its Q2 results on November 12, 2024, revealing a significant growth in both topline and profit. In terms of stock performance, Natco Pharma experienced a -2.19% return over the past week; however, the company has delivered a robust 40.5% return in the last six months and an impressive 71.42% year-to-date return. …

Pharma Natco Pharma Growth Q2 Live Natco

1 month, 1 week ago

Zydus Lifesciences reports double-digit growth in Q2, revenue up 20%

Live Mint

Zydus Lifesciences Ltd announced strong double-digit growth in line with estimates, on the back of sustained growth across its key businesses, in its consolidated financial results for the September quarter on Tuesday. The company’s US formulations business grew 30% y-o-y, registering a revenue of ₹2,417 crore. The company’s active pharmaceuticals ingredients business saw a degrowth of 15% year-on-year with ₹119 …

Business India Growth Company Revenue Crore Quarter

1 month, 2 weeks ago

Govt unveils new schemes for meditech sector

Live Mint

The government on Friday launched a scheme aimed at strengthening the medical devices industry with an initial outlay of ₹500 crore for three years 2024-2025 to 2026-27. It consists of five sub-schemes—common facilities for medical devices clusters with an outlay of ₹100 crore, marginal investment for reducing import dependence, capacity building and skill development for medical devices and medical device …

India Medical Industry Indian Device

1 month, 2 weeks ago

Home remedy: Indian pharma bets on domestic brands to combat US generics slowdown

Live Mint

Indian pharma companies have long been key providers of generic medicines to the US market, accounting for 47% of all generic prescriptions in 2022, according to a recent report by the IQVIA Institute. Branded for growth Mankind Pharma Ltd, which earns 91% of its revenue from its domestic business and has a prescriber penetration rate of almost 84% as of …

Business India Indian Companies Sales Pharma Reddy

1 month, 2 weeks ago

Alembic Pharmaceuticals Q2 Results Live: Profit Rise by 12.33% YOY

Live Mint

Alembic Pharmaceuticals Q2 Results Live : Alembic Pharmaceuticals declared their Q2 results on 07 Nov, 2024, reporting a topline increase of 3.33% and a profit rise of 12.33% year-over-year. Operating income saw a significant jump, up by 8.24% quarter-over-quarter and an impressive 29.09% year-over-year, indicating strong operational efficiency despite rising expenses. In terms of stock performance, Alembic Pharmaceuticals has faced …

Pharmaceuticals Growth Q2 Alembic

1 month, 2 weeks ago

Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY

Live Mint

Dr Reddy's Laboratories Q2 Results: Dr Reddy's Laboratories announced its July-September quarter results for fiscal 2024-25 on Tuesday, November 5, reporting a drop of 9.5 per cent in consolidated net profit to ₹1,342 crore, compared to ₹1,482 crore in the corresponding period last year. Dr Reddy's Laboratories Q2 Results: Key Metrics The drugmaker's total revenue from operations in the second …

India Revenue Crore Cent North America Net Profit Dr Reddy

1 month, 3 weeks ago

Diwali Stock Market: A Dip to Consider for Long-Term Investors

Live Mint

The article highlights the long-term potential of India's stock market, with a focus on sectors like Financials, Pharmaceuticals, and Railways/Infrastructure. The article acknowledges the potential impact of the 2024 US presidential election on global capital flows, but emphasizes that India's strong macro growth story and attractive valuations remain favorable for long-term investors. The article recommends patient long-term investors to capitalize …

Technology Pharmaceuticals Financials Railways/Infrastructure Infrastructure New Delhi

Zomato Q2 Results Preview: Strong Revenue and Profit Outlook

Live Mint

Zomato is expected to announce significant revenue and net profit growth for the September quarter of FY 2024-25, driven by the expansion of its food delivery operations. Analysts predict a 63 per cent YoY revenue growth, with a significant contribution from the Hyperpure and Blinkit divisions. The company is also expected to report an 18.2 per cent YoY growth in …

Entertainment Business Law Technology

4 months, 3 weeks ago

Sun Pharma net profit up 29% in Q1 FY25 on cut in raw material cost

The Hindu

Sun Pharma reported Q1 net profit grew 29% to ₹2,878.94 crore from ₹2,232.05 crore in the year-earlier period on shrinking material costs and revenue expansion The company’s revenue from operations rose 6% to ₹12,652.7 crore in Q1 FY25 from ₹11,940.8 crore in the same quarter of the previous year. Cost of materials consumed dropped 16% in the reporting quarter to …

Crore Sun Pharma Raw Material Q1 Fy25

4 months, 3 weeks ago

Stocks to watch: Ambuja Cements, Maruti, Sun Pharma, M&M, Adani Power, Infosys

Live Mint

Ambuja Cements: The company reported a consolidated profit of ₹646.31 crore for Q1FY25, a 28.6% YoY decline due to rising expenses and lower revenues. Tata Steel: The company reported a 51% jump in consolidated net profit to ₹960 crore for Q1FY25, up from ₹634 crore YoY, but missed analysts’ expectations of ₹1,025 crore. Redington: The company reported a 15% YoY …

India Company Revenue Profit Crore Reported Rbi

4 months, 3 weeks ago

Sun Pharma Q1 Preview: R&D spends to hit margins; profits may rise 10%

Business Standard

India’s biggest drugmaker, Sun Pharmaceuticals is scheduled to deliver its April-June quarterly earnings for the financial year 2024-25 on Thursday, August 1, 2024. According to analyst estimates compiled by Business Standard, Sun Pharma may see its average revenue rise by 7.68 per cent year-on-year to Rs 12,857 crore as against Rs 11,940 in the first quarter of FY24. Sequentially the …

Growth Pharma Cent Quarter Sun Pharma Ebitda

4 months, 4 weeks ago

Mankind pharma share price opens 4.6% higher as is set to buy 100% stake in Bharat Serum and Vaccines

Live Mint

Stock Market Today: Mankind Pharma share price opened 4.6% higher post to its announcements pertaining to acquisition of stakes in Bharat Serums and Vaccines Limited. Mankind Pharma announced having entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Limited from Advent International, one of the key private equity investors. Deal valuation Mankind Pharma said …

Vaccines Mankind Pharma Bharat Serums Serum Ebitda Vaccines Limited

4 months, 4 weeks ago

Mankind Pharma to acquire BSV for ₹13,630 crore

The Hindu

Mankind Pharma Ltd said it had entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Ltd from private equity firm Advent International for an enterprise value of about ₹13,630 crore subject to closing related adjustments. “This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian …

Pharma Mankind Pharma Mankind Bsv

5 months ago

Guideline promotes pharma innovation

China Daily

An employee checks equipment at a pharmaceutical plant in Lianyungang, Jiangsu province. GENG YUHE/FOR CHINA DAILY China has adopted a guideline to promote the development and availability of innovative drugs, with price management improvements, medical insurance payments, commercial insurance coverage, as well as investment and financing topping the work agenda. Meanwhile, China could draw inspiration from international practices by supporting …

Insurance China Medical Drugs Innovative Pharmaceutical Pharma

5 months ago

Guideline promotes pharma innovation

China Daily

An employee checks equipment at a pharmaceutical plant in Lianyungang, Jiangsu province. GENG YUHE/FOR CHINA DAILY China has adopted a guideline to promote the development and availability of innovative drugs, with price management improvements, medical insurance payments, commercial insurance coverage, as well as investment and financing topping the work agenda. Meanwhile, China could draw inspiration from international practices by supporting …

Insurance China Medical Drugs Innovative Commercial Pharmaceutical

6 months, 1 week ago

Mankind Pharma in talks with PE for consortium bid of Bharat Serums: Report

Live Mint

Mankind Pharma is in talks with many private equity companies to form a joint bid to acquire Bharat Serums and Vaccines in a consortium, the Hindu BusinessLine reported, citing sources. Bain Capital, Blackstone, Carlyle, and KKR expressed interest in BSV after its current owner, Advent International, put it up for sale. While Mankind is in talks with these firms, the …

Blackstone Bsv

6 months, 2 weeks ago

Could Apollo Hospitals’ expansion plan help its stock recover?

Live Mint

Apollo Hospitals Enterprise Ltd investors are yet to get over the disappointment of a lower-than-expected valuation in the stake sale of its pharmacy business. Stake sale to Advent International Based on an equity transaction by Advent International Private Equity, the pharmacy business forms just about 15% of the company’s total market capitalisation of ₹85,250 crore. Little room for multiple expansion …

Business Healthcare Market Healthcare Services Eve Crore Pharmacy

7 months ago

Sun Pharma Q4 net rises 34% to ₹2,654 crore

The Hindu

Sun Pharmaceutical Industries Ltd. reported consolidated FY24 Q4 net profit grew 34% to ₹2,654 crore from ₹1,984 crore in the year earlier period. The firm’s FY24 consolidated net profit grew 13% to ₹9,576 crore from ₹8,473 crore. This is in addition to the interim dividend of ₹8.5 per share paid in FY24, taking the total to ₹13.5 per share in …

Board Crore Fy24 Q4 Net Q4 Net Fy24 Q4

7 months ago

AstraZeneca aims for $80 billion in total revenue by 2030

Hindustan Times

AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its existing oncology, biopharmaceuticals and rare disease portfolio. The Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier expected to launch at least 15 new medicines …

Billion Drug 2030

7 months, 3 weeks ago

Injectables maker Maiva Pharma raises ₹1,000 crore to set up new manufacturing unit

Live Mint

Maiva Pharma, a Bengaluru-based injectables manufacturer, has secured ₹1,000 crore in a mix of primary and secondary funding from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund-IV, led by InvAscent, to set up a new manufacturing plant near Hosur, Tamil Nadu. Maiva already has a plant in Hosur producing sterile injectables in vials and …

Pharma Injectables Maker Maiva Maiva Pharma

8 months ago

Top News on April 22: Arvind Kejriwal insulin row, Reliance Q4 results, Lok Sabha campaign and more

Live Mint

Political parties dominated news headlines on Monday amid the Lok Sabha elections — from the AAP insulin row in Tihar jail to outrage over remarks made by Prime Minister Narendra Modi. Here are some of the top news headlines: Reliance Q4 results Reliance Industries reported an almost flat March quarter net profit amid a recovery in its core oil and …

Israel Bjp Minister Insulin Reliance Insulin Row

8 months, 1 week ago

Persistent shortage of growth hormone frustrates parents and clinicians

NPR

Persistent shortage of growth hormone frustrates parents and clinicians Enlarge this image toggle caption Bridget Bennett for NPR Bridget Bennett for NPR Dr. Jennifer Miller has been an author of dozens of studies about rare endocrine diseases over the last two decades. Sponsor Message A shortage of growth hormone — as well as how insurance companies are handling the problem …

Growth Insurance Patients Drug Miller Npr Sponsor Message

9 months ago

Binny Bansal invests ₹200 crore more in startup Curefoods of ex-Flipkart executive: What we know

Hindustan Times

Flipkart co-founder Binny Bansal's fund Three State Ventures pumped an additional ₹200 crores in Accel-backed cloud kitchen startup Curefoods. Binny Bansal Curefoods funding: Binny Bansal’s additional funding is part of the firm’s ongoing round that started in April of 2023 where it raised ₹ 300 crore. Binny Bansal’s additional funding is part of the firm’s ongoing round that started in …

Crore Round Flipkart Binny Bansal Curefoods

9 months, 1 week ago

Pharmaceuticals Department forms panel to reform prices of drugs and medical devices

The Hindu

With the aim of reforming the pricing framework for drugs and medical devices, the Department of Pharmaceuticals has constituted a committee, which is expected to submit its report within the next three months. The committee is mandated to give inputs regarding institutional reforms within the National Pharmaceutical Pricing Authority as well as balancing price and availability of essential medicines, while …

Industry Pharmaceuticals Medical Devices Pharmaceutical Pharma Committee Department

10 months, 2 weeks ago

AstraZeneca sees profits surge and forecasts further growth in 2024

The Independent

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Drugs giant AstraZeneca has more …

Billion Astrazeneca Dollars

10 months, 3 weeks ago

Pfizer stays the course on 2024 outlook after delivering better earnings than Wall Street forecast

Associated Press

Pfizer turned in a better-than-expected fourth quarter, boosted by products outside the drugmaker’s slumping COVID-19 vaccine and treatment. The New York drugmaker also said Tuesday it’s reaffirming its forecast for 2024, a month after surprising Wall Street with an initial outlook that missed consensus. In the fourth quarter, Pfizer said it booked 8% operational revenue growth outside its market-leading COVID …

Share Billion Quarter Wall Street Pfizer Paxlovid

11 months ago

Q3 Result Preview: Sun Pharma to lead with highest qoq rise in the US-Jefferies

Live Mint

Q3 Result Preview: The favorable trend seen by Indian Pharma companies on earnings growth during the first half of FY24 may continue during the December quarter too. Analysts at Jefferies India Pvt Ltd expect the current benign US pricing environment to continue and believe most of their coverage firms will clock sequential sales growth in the quarter. Lupin will Dr …

Growth Indian Companies Sales Pharma Strong Jefferies

11 months, 1 week ago

Budget 2024: Pharma industry seeks conducive policies

Live Mint

In run-up to the interim Budget 2024, the pharma industry has sought conducive policies that provide benefits in terms of both direct and indirect taxes. There is a high risk, long gestation period and low success rate in research, and therefore, there is a need for continuous investments, Indian Pharmaceutical Alliance secretary general Sudarshan Jain said in a statement. “The …

Budget Pharma Jain Conducive Policies Industry Seeks Pharma Industry

11 months, 1 week ago

Outlook 2024: 2 key reasons why Jefferies expect subdued pharma returns vs 2023

Live Mint

Outlook 2024: The Indian pharmaceutical companies saw a favorable 2023 as their earnings were aided by growth in the Domestic and US markets catching pace. Analysts at Jefferies India Pvt Ltd in their report on outlook for 2024 say that Pharma index outperformed Nifty by 14% in CY23 mainly led by valuation rerating. Lack of positive earnings surprise may keep …

Market Indian Pharma Jefferies Dr Reddy Rerating

1 year ago

Innova Captab IPO Day 1: GMP, subscription, review, other details. Apply or not?

Live Mint

Innova Captab IPO: The initial public offering of Innova Captab Limited has opened today and it will remain open for subscribers till 26th December 2023. Important Innova Captab IPO details 1] Innova Captab IPO GMP: Shares of the pharma company are available at a premium of ₹215 in grey market today, say market observers. 2] Innova Captab IPO price: The …

Company Grey Market Pharma Issue Public Book Bse

1 year ago

Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer

Associated Press

Pfizer heads into 2024 with a lower-than-expected sales forecast for its COVID-19 vaccine and treatment after weaker demand had already forced it to trim 2023 projections. The drugmaker announced on Wednesday initial expectations for the new year that include about $8 billion in combined sales from its Comirnaty vaccine and the treatment Paxlovid. Two weeks later, Pfizer said sales of …

Treatment Billion Vaccine Wall Street Pfizer

1 year ago

Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

Associated Press

AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. The deal delivers Elahere, an ImmunoGen ovarian cancer treatment that AbbVie says could eventually reap billions of dollars in annual sales and drive long-term revenue growth. Elahere brought in $105.2 million in revenue in …

Humira Immunogen Abbvie Elahere

1 year ago

India pharma industry to reach $130 billion by 2030

The Hindu

The Indian pharmaceutical industry is expected to reach $130 billion mark by 2030 said a top industry executive at the CPHI & PMEC India expo. This growth is propelled by expanding market opportunities, heightened demand in the USA, and critical shortages of medicines in the U.S. and Europe,” said Dr. Veeramani S.V., Chairman, Pharmaceuticals Export Promotion Council of India. Anil …

India Growth Industry Indian Pharmaceutical Pharma Billion

1 year, 1 month ago

Aurobindo Pharma share price rises more than 1% on regulatory clearance of plant

Live Mint

The news on the successful Completion of US FDA Inspection at Unit I & III of Aurobindo Pharma Ltd lifted investor sentiments and the share prices gained of Aurobindo Pharma gained more than 1% in morning trades on Monday, on a day when benchmark indices were trading in red. Aurobindo Pharma in its filing on the exchanges said that United …

Aurobindo Regulatory Clearance Pharma Share

1 year, 1 month ago

Apollo Hospitals, Narayana scale 52-week high on Q2 results

Live Mint

Apollo Hospitals Enterprise Ltd, Narayana Hrudayalaya Ltd share price scaled 52-week highs on Friday while Fortis Healthcare, Max Healthcare Institute Limited, Global Health ltd are trading close to their highs seen recently. The ARPOB have seen good double-digit growth with the exception of Global Healthcare or Medanta that saw the new Hospital In Patna pulling down overall average ARPOB growth. …

Growth Hospitals Max Jefferies Medanta Fortis Arpob

1 year, 1 month ago

Jubilant Pharmova stock gains 6.45% in an overall weak market; here’s why

Live Mint

Jubilant Pharmova witnessed a 6.45% surge in its share price, reaching ₹438.90 apiece, during early trade on Monday after the company's Radiopharma business received ANDA approval for Technetium Sulfur Colloid Injection. The company, in an exchange filing on Friday, said that “Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Draximage Inc. received approval from the US FDA with regards to the …

Business Company Crore Approval Jubilant Sulfur Colloid Radiopharma

Gland Pharma to announce four complex injectables during FY22; Q2 profit rises 38%

History of this topic

Gland Pharma Q2 net declines 16% to ₹163.5 cr.

Gland Pharma Q4 net profit declines 72% year-on-year

Discover Related